CC-1065 analogues bearing different DNA-binding subunits: Synthesis, antitumor activity, and preliminary toxicity study

Journal of Medicinal Chemistry

Volumn 46, Issue 4, 2003, Pages 634-637

  Wang, Yuqiang ^a   Li, Lianfa ^b   Ye, Wenqing ^a   Tian, Zhiming ^c   Jiang, Wei ^a   Wang, Hong ^a   Wright, Susan C ^a   Larrick, James W ^a  

^a Panorama Research Inc   (United States)

^b QILU UNIVERSITY OF TECHNOLOGY   (China)

^c INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RACHELMYCIN; RACHELMYCIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL BOND; CYTOPATHOGENIC EFFECT; DNA BINDING; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN;

ACUTE TOXICITY TESTS; ANIMALS; ANTINEOPLASTIC AGENTS; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; INDOLES; LEUCOMYCINS; LEUKEMIA L1210; MICE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL RATE;

EID: 0037434543     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0203433     Document Type: Article

References (21)

1. Hanka, L. J.; Dietz, A.; Gerpheide, S. A.; Kuentzel, S. L.; Martin, D. G. CC-1065 (NSC-218223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays, and taxonomy of the producing microorganisms. J. Antibiot. 1978, 31, 1211-1217.
2. Martin, D. G.; Chidester, C. G.; Duchamp, D. J.; Mizsk, S. A. Structure of CC-1065 (NSC-218223), a new antitumor antibiotic. J. Antibiot. 1980, 33, 902-903.
3. Martin, D. G.; Biles, C.; Gerpheide, S. A.; Hanka, L. J.; Kroeger, W. C.; McGovren, J. P.; Mizsk, S. A.; Neil, G. L.; Stewart, J. C.; Visser, J. CC-1065 (NSC-218223), a potent new antitumor agent, improved production and isolation, characterization and antitumor activity. J. Antibiot. 1981, 34, 1119-1125.
4. Bhuyan, B. K.; Newell, K. A.; Crampton, S. L.; Von Hoff, D. D. CC-1065 (NSC-218223), a most potent antitumor agent: Kinetics of inhibition of growth, DNA synthesis and cell survival. Cancer Res. 1982, 42, 3532-3537.
5. Swenson, D. H.; Li, L. H.; Hurley, L. H.; Rokem, J. S.; Petzold, G. L.; Dayton, B. D.; Wallace, T. L.; Lin, A. H.; Krueger, W. K. Mechanism of interaction of CC-1065 (NSC-218223) with DNA. Cancer Res. 1982, 42, 2021-2020.
6. Hurley, L. H.; Reynolds, V. L.; Swenson, D. H.; Petzold, G. L.; Scahill, T. A. Reaction of the antitumor antibiotics CC-1065 with DNA: Structure of a DNA adduct with DNA sequence specificity. Science 1984, 226, 843-844.
7. Reynolds, V. L.; Molineaux, I. J.; Kaplan, D. J.; Swenson, D. H.; Hurley, L. H. Reaction of antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry 1985, 24, 6220-6237.
8. Chiang, S. Y.; Welch, J.; Rauscher, F. J., III; Beerman, T. A. Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Biochemistry 1994, 33, 7033-7040.
9. McGovren, J. P.; Clarke, G. L.; Pratt, E. A.; DeKoning, T. F. Preliminary toxicity studies with the DNA-binding antibiotic CC-1065. J. Antibiot. 1984, 37, 63-70.
10. Boger, D. L.; Stauffer, F.; Hedrick, M. P. Substituent effects within the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065. Bioorg. Med. Chem. Lett. 2001, 11, 2021-2024.
11. Wang, Y.; Gupta, R.; Huang, L.; Lown, J. W. Synthesis and antitumor activity of CC-1065 functional analogues possessing different electron-withdrawing substituents and leaving groups. J. Med. Chem. 1993, 36, 4172-4182.
12. 1H NMR and restrained molecular dynamics simulation. J. Am. Chem. Soc. 1995, 117, 8917-8925.
13. Wang, Y.; Gupta, R.; Huang, L.; Luo, W.; Lown, J. W. Design, synthesis, cytotoxic properties and preliminary DNA sequencing evaluation of CPI-N-methylpyrrole hybrids. Enhancing effect of a trans double bond linker and role of the terminal amide functionality on cytotoxic potency. Anti-Cancer Drug Des. 1996, 11, 15-34.
14. Lown, J. W.; Wang, Y.; Luo, W. Cyclopropylpyrroloindole-Oligopeptide Anticancer Agents. U.S. Patent 5,502,068, March 1996.
15. Amishiro, N.; Okamoto, A.; Murakata, C.; Tamaoki, T.; Okabe, M.; et al. Synthesis and antitumor activity of duocarmycin derivatives: modification of segment-A of A-ring pyrrole compounds. J. Med. Chem. 1999, 42, 2946-2960.
16. Amishiro, N.; Nagamura, S.; Kobayashi, E.; Okamoto, A.; Gomi, K.; et al. Synthesis and antitumor activity of duocarmycin derivatives: A-ring pyrrole compounds bearing beta-(5′,6′,7′-trimethoxy-2′-indolyl)acryloyl group. Bioorg. Med. Chem. 2000, 8, 1637-1643.
17. Wang, Y.; Yuan, H.; Ye, W.; Wright, S. C.; Wang, H.; Larrick, J. W. Synthesis and preliminary biological evaluations of CC-1065 analogues: effects of different linkers and terminal amides on biological activity. J. Med. Chem. 2000, 43, 1541-1549.
18. Aristoff, P. A.; Johnson, P. D. Synthesis of CBI-PDE-I-dimer, the benzannelated analogue of CC-1065. J. Org. Chem. 1992, 57, 6234-6239.
19. Aristoff, P. A. CC-1065 Analogs: Sequence Specific DNA-Alkylating Antitumor Agents. Adv. Med. Chem. 1993, 2, 67-110.
20. van Tellingen, O.; Nooijen, W. J.; Schaaf, L. J.; van der Valk M.; van Asperen J.; Henrar, R. E. C.; Beijnen, J. H. Cancer Res. 1998, 58, 2410-2416.
21. Alberts, S. R.; Erlichman, C.; Reid, J. M.; Sloan, J. A.; Ames, M. M.; Richardson, R. L.; Goldberg, R. M. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin. Cancer Res. 1998, 4, 2111-2117.